Psyence Biomedical Ltd. is consolidating its common shares through a 1-for-6.25 reverse stock split. The company now expects its shares to begin trading on a post-consolidated basis at the opening of the market on February 2, 2026.
At the effective time, every 6.25 issued and outstanding common shares will be combined into one share, and the number of shares underlying outstanding warrants and other equity instruments and their exercise prices will be adjusted proportionately under their terms. As of January 21, 2026, Psyence BioMed had 6,388,604 common shares issued and outstanding; following the consolidation it will have 1,022,177 common shares issued and outstanding.
The reverse split is intended, among other things, to support the company’s ability to maintain compliance with Nasdaq continued listing standards. The consolidation applies uniformly to all shareholders, with only minor differences from rounding of fractional shares. Continental Stock Transfer & Trust Company will act as exchange and transfer agent, and most shareholders will not need to take action.
Psyence Biomedical Ltd. filed a report explaining that its annual and special shareholder meeting, originally set for January 22, 2026, was adjourned because not enough shares were represented to reach quorum. The meeting has been rescheduled to February 12, 2026 at 9:00 a.m. New York time / 4:00 p.m. Cape Town time in Cape Town, South Africa, and the record date for voting remains December 23, 2025. The company is working with its proxy agents to obtain sufficient shareholder participation and notes that there is no assurance quorum will be reached, highlighting potential delays or challenges around completing the planned meeting business.